Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 385

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 385
---
 implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. Some states have also enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states.

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for ZELSUVMI or our approved product candidates or additional pricing pressures. We cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.

#### Human Capital
As of April 15, 2025, LNHC had approximately 28 full-time employees, all located in the United States. None of our employees are represented by a labor union or covered by a collective bargaining agreement. LNHC is in the process of hiring a sales, marketing and commercialization team and expect the headcount to increase to approximately 85 people to execute the launch of ZELSUVMI and supportive commercialization activities by mid-year 2025.

LNHC’s human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants.

#### Insurance
We currently maintain product liability insurance coverage for our products and clinical trials, if applicable, in amounts consistent with industry standards. However, insurance coverage is becoming increasingly expensive, and we may not be able to obtain or maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.

<div align='center'>216</div>

#### TABLE OF CONTENTS

#### Corporate Information
LNHC, Inc. is incorporated under the laws of the State of Delaware. The Company’s principal executive offices are located at:

LNHC, Inc.

4020 Stirrup Creek Drive, Suite 110

Durham, NC 27703

Phone: 1-919-908-2400

Email: contact@LNHC.com

<div align='center'>217</div>

#### TABLE OF CONTENTS

### MANAGEMENT’S DISCUSSION